Venrock

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Venrock
Type Limited liability company
Industry Venture Capital
Founded 1969
Headquarters Palo Alto, California, United States
Products Investments
Website www.venrock.com

Venrock, a compound of "Venture" and "Rockefeller", is a pioneering venture capital firm formed in 1969 to build upon the successful investing activities of the Rockefeller family that began in the late 1930s. It has offices in Palo Alto, California, New York City, Cambridge, Massachusetts, and Israel.

History[edit]

The pioneering venture capitalist Laurance S. Rockefeller (1910–2004), was the fourth of the six children of John D. Rockefeller, Jr.. In January, 1946 he formed Rockefeller Brothers, Inc., one of the first postwar venture-capital operations, starting with a capitalization of $1.5 million. There were six partners in all, the five famed brothers and their sister, Abby. In August, 1969, the firm became known as Venrock.

Over the years Laurance became well known as an investor in enterprises based on science and technology. His investment interests included the fields of aviation, aerospace, electronics, high temperature physics, composite materials, optics, lasers, data processing, thermionics and nuclear power. It has invested more than $2.5 billion in more than 440 companies, resulting in 125 IPO’s over the past 40 years.

Venrock focuses its investments on early-stage and start-up companies in information technology and emerging technologies. These include: Intel, Apple, AppNexus, StrataCom, Check Point Software, DoubleClick, 3Com Corporation, Mosaic, PGP, Itek, Digex, Media6Degrees, Shape Security, Smartling, Phoenix, Second Rotation (gazelle) and CTERA Networks. It also has a significant venture in the nascent nanotechnology field, with early funding of Nanosys and the nanotech division of Du Pont.[1]

In the healthcare sector, with well-known and respected partners such as Bryan Roberts, Venrock has invested in HealthSouth Corporation, MedPartners, Inc., Castlight Health, Caliper Technologies Corporation, Centocor, Geron,[1] Genetics Institute, Idec Pharmaceuticals Corporation, Illumina, Millennium Pharmaceuticals, Sirna Therapeutics, athenahealth and Sugen.

In 1999, Venrock and Kleiner Perkins Caufield & Byers, in coordination with Michael D. West, now CEO of BioTime,[2] invested in West's Geron Corporation (NASDAQGERN).[3] Venrock General Partner Patrick Latterell served on the company's Board of Directors[4] and the company went on to initiate the first embryonic stem cell-based clinical trial.[5]

On July 19, 2013 it was announced that Daniel Loreto, engineering lead for Twitter and Google is joining Venrock as EIR.[6]

See also[edit]

Further reading[edit]

    • Harr, John Ensor, and Peter J. Johnson. The Rockefeller Century: Three Generations of America's Greatest Family. New York: Charles Scribner's Sons, 1988.
    • Winks, Robin W. Laurance S. Rockefeller: Catalyst for Conservation, New York: Island Press, 1997.

References[edit]

External links[edit]